Stockholders Approve Plans Authorizing 1.99M New Shares, Potential 44% Dilution

summarizeSummary

Stockholders approved an increase of 1.99 million shares for incentive and employee stock purchase plans, representing a potential dilution of over 44% for current shareholders.

check_boxKey Events

• Increased Incentive Plan Shares

  Stockholders approved an amendment to the 2021 Incentive Plan, increasing the number of shares authorized for issuance by 400,000 shares for future awards.

• Expanded Employee Stock Purchase Plan (ESPP)

  The Employee Stock Purchase Plan (ESPP) was amended and approved, increasing the total shares reserved for issuance from 310,000 to 1,900,000, a net increase of 1,590,000 shares.

• Significant Potential Dilution

  The combined authorization of 1,990,000 new shares for these plans represents a potential dilution of approximately 44.12% relative to the company's estimated outstanding shares.

• Routine Annual Meeting Approvals

  Stockholders also elected two Class II Directors, ratified Grant Thornton LLP as the independent auditor, and approved executive compensation in a non-binding advisory vote.

auto_awesomeAnalysis

Harvard Bioscience stockholders approved amendments to its 2021 Incentive Plan and Employee Stock Purchase Plan (ESPP), authorizing the issuance of an additional 1,990,000 shares of common stock for future awards and purchases. This represents a significant potential dilution of approximately 44% if all authorized shares were issued, which could impact existing shareholder value.